Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (IN201817027046) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS

Office : India
Application Number: 201817027046 Application Date: 19.07.2018
Publication Number: 201817027046 Publication Date: 16.11.2018
Publication Kind : A
Prior PCT appl.: Application Number:PCTUS2017017435 ; Publication Number: Click to see the data
IPC:
A61K 45/06C
[IPC code unknown for ERROR IPC Code incorrect: invalid subgroup (0=>999999)!]
Applicants: IMMUNOMEDICS, INC.
Inventors: CHANG, Chien-Hsing
GOLDENBERG, David M.
Priority Data: 62/293530 10.02.2016 US
62/329788 29.04.2016 US
62/336985 16.05.2016 US
Title: (EN) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
Abstract:
(EN) The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
Also published as:
CA3011372CN108601841EP3413914WO/2017/139623